DNA insider plans sale of 972 Class A shares

Ginkgo Bioworks Holdings (symbol DNA) filed a notice of proposed sales of restricted stock under Rule 144.

Accepted by SEC EDGAR 01/20/2026 - 04:15 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ginkgo Bioworks Holdings (symbol DNA) filed a notice of proposed sales of restricted stock under Rule 144. The filing covers a planned sale of 972 Class A shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 8,667.23 and 48,523,595 Class A shares outstanding.

The 972 Class A shares were acquired on 01/16/2026 through restricted stock vesting from the issuer as compensation, with payment dated 01/16/2026. The notice also discloses that Steven Coen previously sold 736 Class A shares on 12/15/2025 for gross proceeds of 6,540.02.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing by DNA relate to?

The Form 144 filing for DNA relates to a proposed sale under Rule 144 of 972 Class A shares of the issuer's stock on the NYSE, with an aggregate market value of 8,667.23.

Who is selling shares in this DNA Form 144 and how many?

The filing shows that Steven Coen is the person for whose account the securities are to be sold, with a proposed sale of 972 Class A shares and a prior sale of 736 Class A shares on 12/15/2025.

How were the DNA shares being sold under Form 144 acquired?

The 972 Class A shares covered by the notice were acquired on 01/16/2026 via restricted stock vesting from the issuer as compensation, with the acquisition and payment both dated 01/16/2026.

What are the recent share sales disclosed for DNA in the last 3 months?

The notice discloses that Steven Coen sold 736 Class A shares on 12/15/2025, generating 6,540.02 in gross proceeds.

How many DNA Class A shares are outstanding according to this Form 144?

The securities information section lists 48,523,595 Class A shares as the number of shares or other units outstanding.

Which broker and exchange are involved in the proposed DNA share sale?

The proposed sale of 972 Class A shares is through Fidelity Brokerage Services LLC, with trades expected on the NYSE and an approximate sale date of 01/20/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001977441
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Ginkgo Bioworks Holdings, Inc.
SEC File Number	001-40097
Address of Issuer	27 DRYDOCK AVENUE 8TH FLOOR BOSTON MASSACHUSETTS 02210
Phone	(877) 442-5362
Name of Person for Whose Account the Securities are To Be Sold	Coen Steven P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	972	8667.23	48523595	01/20/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	01/16/2026	Restricted Stock Vesting	Issuer			972	01/16/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Steven Coen 27 Drydock Avenue 8th Floor Boston MA 02210	Class A	12/15/2025	736	6540.02

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	01/20/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Steven Coen
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)